Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colon Cancer: Incidence, Etiology, and Management

Current Surgery

Volumn 63, Issue 5, 2006, Pages 334-337

  Heinzerling, John H ^a,b   Huerta, Sergio ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

acute abdomen; Avastin; Bevacizumab; bowel perforation; chemotherapy; colon cancer; immunotherapy

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; INFUSION FLUID; IRINOTECAN;

ABSCESS; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; DIGITAL RECTAL EXAMINATION; ENTEROCUTANEOUS FISTULA; GASTROINTESTINAL HEMORRHAGE; HUMAN; INCIDENCE; INTESTINE ANASTOMOSIS; INTESTINE ISCHEMIA; INTESTINE PERFORATION; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECTUM BIOPSY; RECTUM CARCINOMA;

ABDOMEN, ACUTE; ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; INTESTINAL PERFORATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECTAL NEOPLASMS;

EID: 33748426175     PISSN: 01497944     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cursur.2006.06.002     Document Type: Article

References (21)

1. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
2. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
3. Simpson D., Dunn C., Curran M., et al. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs 63 (2003) 2127-2156
4. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29 (2002) 10-14
5. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
6. Kozloff M., Cohn A., Christiansen N., et al. Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): preliminary results from a larger registry in the U.S. J Clin Oncol (Meeting Abstracts) 23 (2005) 3566
7. Skillings J.R., Johnson D.H., Miller K., et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol (Meeting Abstracts) 23 (2005) 3019
8. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
9. Kozloff M., Cohn A., Christiansen N., et al. Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): preliminary results from a larger registry in the U.S. J Clin Oncol (Meeting Abstracts) 23 (2005) 3566
10. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
11. Gordon M.S., and Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 69 suppl 3 (2005) 25-33
12. Kozloff M., Cohn A., Christiansen N., et al. Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): preliminary results from a larger registry in the U.S. J Clin Oncol (Meeting Abstracts) 23 (2005) 3566
13. Kriwanek S., Armbruster C., Dittrich K., et al. Perforated colorectal cancer. Dis Colon Rectum 39 (1996) 1409-1414
14. Sakakura C., Hagiwara A., Nakanishi M., et al. Bowel perforation during chemotherapy for non-hodgkin's lymphoma. Hepatogastroenterology 46 (1999) 3175-3177
15. Fischer L., Kimose H.H., Spjeldnaes N., et al. Late progress of radiation-induced proctitis. Acta Chir Scand 156 (1990) 801-805
16. Pricolo V.E., and Shellito P.C. Surgery for radiation injury to the large intestine. Variables influencing outcome. Dis Colon Rectum 37 (1994) 675-684
17. Haboubi N.Y., Schofield P.F., and Rowland P.L. The light and electron microscopic features of early and late phase radiation-induced proctitis. Am J Gastroenterol 83 (1988) 1140-1144
18. Haboubi N.Y., Schofield P.F., and Rowland P.L. The light and electron microscopic features of early and late phase radiation-induced proctitis. Am J Gastroenterol 83 (1988) 1140-1144
19. Tomori H., Yasuda T., Shiraishi M., et al. Radiation-associated ischemic coloproctitis: report of two cases. Surg Today 29 (1999) 1088-1092
20. Skillings J.R., Johnson D.H., Miller K., et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol (Meeting Abstracts) 23 (2005) 3019
21. Ratner M. Genentech discloses safety concerns over Avastin. Nat Biotechnol 22 (2004) 1198